Core Viewpoint - SciSparc Ltd. is expanding its joint venture MitoCareX Bio Ltd. to include research on pancreatic cancer following positive initial in-vitro results, indicating a significant growth in its therapeutic focus [1][2][3]. Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [6]. Research and Development - MitoCareX has achieved promising results in drug discovery for pancreatic cancer, utilizing a computationally advanced platform that screened millions of small molecules to identify potential anti-cancer treatments [2][3]. - The company is developing a predictive AI model to explore broader chemical spaces, aiming to discover novel anti-cancer compounds targeting the mitochondrial SLC25 protein family [4]. Market Context - Pancreatic cancer is noted as one of the most aggressive cancers, with a 5-year survival rate of only 12% as of 2023, highlighting a significant unmet medical need in this area [5].

On Monday, SciSparc Ltd SPRC stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro.SciSparc announced, as part of its ongoing collaboration with Clearmind Medicine Inc. CMND, the publication of a European patent application submitted by Clearmind under the European Patent Office for combination therapy of MEAI and N-Acylethanolamines for binge behavior, including alcohol consumption, eating, tobacco consumption, shopping, a ...

TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental ...

U.S. stocks traded slightly lower toward the end of trading, with the S&P 500 edging lower on Thursday.The Dow traded down 0.03% to 43,283.94 while the NASDAQ fell 0.05% to 20,021.98. The S&P 500 also fell, dropping, 0.07% to 6,035.54.Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend YieldsLeading and Lagging SectorsIndustrials shares rose by 0.3% on Thursday.In trading on Thursday, consumer discretionary shares dipped by 0.5%.Top HeadlineU.S. i ...

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax’s direct import ...

According to the LOI, SciSparc's pharmaceuticals assets are valued at approximately US$11.6 million TEL AVIV, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it had signed an amendment to its non-binding letter of intent (the "LOI") to spin off by reverse merger its advanced clinica ...

Exhibit 99.1 SCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 UNAUDITED INDEX Page | Consolidated Statements of Financial Position | 2-3 | | --- | --- | | Consolidated Statements of Profit or Loss and Other Comprehensive Loss | 4 | | Consolidated Statements of Changes in Equity (Deficit) | 5-7 | | Consolidated Statements of Cash Flows | 8-10 | | Notes to Interim Consolidated Financial Statements | 11-23 | SCISPARC LTD. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | | | | June 30, ...

FDA confirms that SciSparc's study may proceed only a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that the U.S. Food and Drug Administration ("FDA") has confirmed that its investigational new drug ("IND") application for its first in class dru ...

The intended selling valuation represents an increase of 47% from the valuation at the time of SciSparc's initial investment in MitoCareX Bio TEL AVIV, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it has signed a non-binding letter of intent ("LOI") to sell its entire ownership interest in MitoCareX Bi ...

FDA confirms that SciSparc's study may proceed following the application submission a month ago TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that the U.S. Food and Drug Administration ("FDA") has confirmed that its investigational new drug ("IND") application for its first ...